
|Articles|June 1, 2002
The potency/efficacy of the fluoroquinolones in community-acquired pneumonia
This article reviews the efficacy of fluoroquinolones for treating community-acquired pneumonia (CAP) and discusses clinical advantages of fluoroquinolones relative to other drug classes. Of 19 randomized, controlled trials comparing a fluoroquinolone with another agent or combination of agents in CAP, 6 trials have demonstrated superiority of the fluoroquinolone with respect to clinical and/or bacteriologic efficacy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
LucyRx and Abarca to merge
2
Hospitals facing financial headwinds can't afford to ignore the mounting threats to 340B
3
FDA approves new sunscreen ingredient, first time in 20 years
4
Updated COVID-19 vaccine cut hospitalization risk by 35% in 2024-2025 season
5
































